《大行報告》花旗下調創科(00669.HK)目標價至152元 評級「買入」
花旗發表評級報告表示,創科(00669.HK)旗下品牌Milwaukee及Ryobi今年收入增長將會分別錄得逾20%及約10%,分別佔去年總銷量約60%及約31%;惟在地板護理銷量應會下跌,呈輕微虧損,佔去年總銷量約9%,故整體收入增長將逾10%,相比早前指引的15%,意味收入單方面受到地板護理業務影響,而電力設備指導則大致上維持不變。
該行表示,基於預期集團收入下跌,因此下調其2022年至23年每股盈測1%至2%,目標價由175元下調至152元,以反映美國宏觀經濟放緩的風險增加,維持其評級為「買入」,仍認為集團是其工業領域首選股,因其管治及執行能力強勁,及更快的市場整合趨勢。(ca/k)
~
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.